CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade AstraZeneca PLC - GBP - AZNl CFD

100.05
1.73%
Market Trading Hours* (UTC) Opens on Friday at 08:00

Mon - Fri: 08:00 - 12:00 12:03 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 2.04
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025261 %
Charges from full value of position ($-4.80)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.025261%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003343 %
Charges from full value of position ($0.64)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003343%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency GBP
Margin 5%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

*Information provided by Capital.com

AstraZeneca PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 101.81
Open* 101.55
1-Year Change* -6.6%
Day's Range* 100.01 - 101.67
52 wk Range 97.78-123.92
Average Volume (10 days) 2.37M
Average Volume (3 months) 41.29M
Market Cap 161.29B
P/E Ratio 34.98
Shares Outstanding 1.55B
Revenue 35.41B
EPS 2.97
Dividend (Yield %) 2.24885
Beta 0.32
Next Earnings Date Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 29, 2024 100.05 -1.76 -1.73% 101.81 101.81 99.99
Feb 28, 2024 101.81 -0.70 -0.68% 102.51 103.29 101.73
Feb 27, 2024 103.05 1.24 1.22% 101.81 103.33 101.81
Feb 26, 2024 102.45 0.36 0.35% 102.09 103.47 101.97
Feb 23, 2024 102.19 2.41 2.42% 99.78 102.41 99.78
Feb 22, 2024 100.03 -0.16 -0.16% 100.19 100.23 98.09
Feb 21, 2024 100.91 -0.10 -0.10% 101.01 101.63 100.53
Feb 20, 2024 101.91 -0.94 -0.91% 102.85 104.13 101.91
Feb 19, 2024 104.03 -0.42 -0.40% 104.45 104.81 103.63
Feb 16, 2024 100.89 2.52 2.56% 98.37 100.97 98.34
Feb 15, 2024 98.27 1.15 1.18% 97.12 98.56 96.61
Feb 14, 2024 96.41 0.13 0.14% 96.28 97.22 95.28
Feb 13, 2024 95.26 -0.27 -0.28% 95.53 96.57 95.26
Feb 12, 2024 94.16 -2.74 -2.83% 96.90 97.07 94.16
Feb 9, 2024 97.41 -1.39 -1.41% 98.80 99.71 96.91
Feb 8, 2024 98.37 -5.92 -5.68% 104.29 104.45 96.90
Feb 7, 2024 104.85 -0.56 -0.53% 105.41 106.39 104.45
Feb 6, 2024 104.51 1.00 0.97% 103.51 105.31 103.03
Feb 5, 2024 103.71 1.82 1.79% 101.89 104.19 101.89
Feb 2, 2024 103.19 0.20 0.19% 102.99 104.91 102.99

AstraZeneca PLC - GBP Events

Time (UTC) Country Event
Sunday, March 3, 2024

Time (UTC)

10:59

Country

GB

Event

AstraZeneca PLC at Macquarie NDR Roadshow - Hong Kong
AstraZeneca PLC at Macquarie NDR Roadshow - Hong Kong

Forecast

-

Previous

-
Monday, March 4, 2024

Time (UTC)

10:59

Country

GB

Event

AstraZeneca PLC at JPMorgan Roadshow - South Korea
AstraZeneca PLC at JPMorgan Roadshow - South Korea

Forecast

-

Previous

-

Time (UTC)

10:59

Country

GB

Event

AstraZeneca PLC at TD Cowen Health Care Conference
AstraZeneca PLC at TD Cowen Health Care Conference

Forecast

-

Previous

-
Tuesday, March 5, 2024

Time (UTC)

10:59

Country

GB

Event

AstraZeneca PLC at Exane BNPP Roadshow - Madrid & Milan
AstraZeneca PLC at Exane BNPP Roadshow - Madrid & Milan

Forecast

-

Previous

-
Thursday, April 25, 2024

Time (UTC)

06:00

Country

GB

Event

Q1 2024 AstraZeneca PLC Earnings Release
Q1 2024 AstraZeneca PLC Earnings Release

Forecast

-

Previous

-
Friday, April 26, 2024

Time (UTC)

13:30

Country

GB

Event

AstraZeneca PLC Annual Shareholders Meeting
AstraZeneca PLC Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 44351 37417 26617 24384 22090
Revenue 44351 37417 26617 24384 22090
Cost of Revenue, Total 8649 9542 5270 4824 4246
Gross Profit 35702 27875 21347 19560 17844
Total Operating Expense 40594 36361 21455 21460 18703
Selling/General/Admin. Expenses, Total 13512 11519 9338 8964 8479
Research & Development 9612 8519 6094 5320 5266
Depreciation / Amortization 4094 3044 1897 1812 1945
Unusual Expense (Income) 5071 3846 -763 863 -953
Other Operating Expenses, Total -344 -109 -381 -323 -280
Operating Income 3757 1056 5162 2924 3387
Interest Income (Expense), Net Non-Operating -815 -819 -716 -766 -775
Other, Net -441 -502 -530 -610 -619
Net Income Before Taxes 2501 -265 3916 1548 1993
Net Income After Taxes 3293 115 3144 1227 2050
Minority Interest -5 -3 52 108 105
Net Income Before Extra. Items 3288 112 3196 1335 2155
Net Income 3288 112 3196 1335 2155
Income Available to Common Excl. Extra. Items 3288 112 3196 1335 2155
Income Available to Common Incl. Extra. Items 3288 112 3196 1335 2155
Dilution Adjustment 0 0
Diluted Net Income 3288 112 3196 1335 2155
Diluted Weighted Average Shares 1560 1427 1313 1301 1267
Diluted EPS Excluding Extraordinary Items 2.10769 0.07849 2.43412 1.02613 1.70087
Dividends per Share - Common Stock Primary Issue 2.89361 2.84245 2.83031 2.89446 2.74532
Diluted Normalized EPS 4.04679 2.22705 1.88804 1.48501 0.85399
Interest Expense (Income) - Net Operating 0 0
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 11416 10879 11207 10982 10771
Revenue 11416 10879 11207 10982 10771
Cost of Revenue, Total 1925 1782 2417 2118 1904
Gross Profit 9491 9097 8790 8864 8867
Total Operating Expense 8960 8330 10113 9737 10232
Selling/General/Admin. Expenses, Total 3592 3196 3469 3353 3340
Research & Development 2570 2299 2525 2357 2431
Depreciation / Amortization 952 954 1034 979 983
Unusual Expense (Income) -285 379 641 1002 1298
Other Operating Expenses, Total 206 -280 27 -72 276
Operating Income 2456 2549 1094 1245 539
Interest Income (Expense), Net Non-Operating -368 -287 -316 -323 -292
Net Income Before Taxes 2088 2262 778 922 247
Net Income After Taxes 1820 1804 902 1642 360
Minority Interest -2 -1 -1 -2 0
Net Income Before Extra. Items 1818 1803 901 1640 360
Net Income 1818 1803 901 1640 360
Income Available to Common Excl. Extra. Items 1818 1803 901 1640 360
Income Available to Common Incl. Extra. Items 1818 1803 901 1640 360
Dilution Adjustment
Diluted Net Income 1818 1803 901 1640 360
Diluted Weighted Average Shares 1560 1560 1560 1559 1560
Diluted EPS Excluding Extraordinary Items 1.16538 1.15577 0.57756 1.05196 0.23077
Dividends per Share - Common Stock Primary Issue 0.91215 0 1.9694 0 0.93017
Diluted Normalized EPS 1.00614 1.34953 0.90705 0.99743 0.80833
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 22593 26244 19544 15563 15591
Cash and Short Term Investments 6405 6398 7992 6218 5680
Cash 1411 1461 1182 755 893
Cash & Equivalents 4755 4868 6650 4614 3938
Short Term Investments 239 69 160 849 849
Total Receivables, Net 9923 8795 5651 5181 4345
Accounts Receivable - Trade, Net 7508 6324 3956 3813 2995
Total Inventory 4699 8983 4024 3193 2890
Prepaid Expenses 1329 1512 1735 865 1436
Other Current Assets, Total 237 556 142 106 1240
Total Assets 96483 105363 66729 61377 60651
Property/Plant/Equipment, Total - Net 9449 10171 8917 8335 7421
Property/Plant/Equipment, Total - Gross 17192 18495 17110 15852 14639
Accumulated Depreciation, Total -7743 -8324 -8193 -7517 -7218
Goodwill, Net 19820 19997 11845 11668 11707
Intangibles, Net 39307 42387 20947 20833 21959
Long Term Investments 1142 1237 1147 1459 922
Note Receivable - Long Term 592 504 325 348 515
Other Long Term Assets, Total 3580 4823 4004 3171 2536
Total Current Liabilities 26293 22594 20307 18117 16292
Accounts Payable 2550 2824 2350 1774 1720
Accrued Expenses 8303 8079 4994 5085 5148
Notes Payable/Short Term Debt 261 294 370 154 160
Current Port. of LT Debt/Capital Leases 5281 1599 2016 1856 1594
Other Current Liabilities, Total 9898 9798 10577 9248 7670
Total Liabilities 59446 66095 51107 48250 48183
Total Long Term Debt 23690 28888 17994 16217 17359
Long Term Debt 22965 28134 17505 15730 17359
Capital Lease Obligations 725 754 489 487 0
Deferred Income Tax 2944 6206 2918 2490 3286
Minority Interest 21 19 16 1469 1576
Other Liabilities, Total 6498 8388 9872 9957 9670
Total Equity 37037 39268 15622 13127 12468
Common Stock 387 387 328 328 317
Additional Paid-In Capital 35155 35126 7971 7941 4427
Retained Earnings (Accumulated Deficit) 1495 3755 7323 4858 7724
Total Liabilities & Shareholders’ Equity 96483 105363 66729 61377 60651
Total Common Shares Outstanding 1549.8 1549.4 1312.67 1312.14 1267.04
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 22501 22839 22266 22593 20224
Cash and Short Term Investments 5115 5812 6462 6405 4898
Cash & Equivalents 4871 5664 6232 6166 4458
Short Term Investments 244 148 230 239 440
Total Receivables, Net 11997 11932 10797 11252 10061
Accounts Receivable - Trade, Net 11300 11092 10289 10521 9336
Total Inventory 5292 5051 4967 4699 5078
Other Current Assets, Total 97 44 40 237 187
Total Assets 96086 96543 96687 96483 94185
Property/Plant/Equipment, Total - Net 9700 9624 9599 9449 9227
Goodwill, Net 19939 19960 20001 19820 19707
Intangibles, Net 37687 38326 39291 39307 39585
Long Term Investments 1290 1143 1234 1142 1102
Note Receivable - Long Term 761 752 682 835 792
Other Long Term Assets, Total 4208 3899 3614 3337 3548
Total Current Liabilities 28588 26375 24860 26293 24850
Payable/Accrued 20542 19738 19210 19040 17694
Notes Payable/Short Term Debt 331 271 568 261 584
Current Port. of LT Debt/Capital Leases 5276 4516 3289 5281 5034
Other Current Liabilities, Total 2439 1850 1793 1711 1538
Total Liabilities 58889 59151 60898 59446 59051
Total Long Term Debt 22969 25051 27646 23690 23681
Long Term Debt 22225 24329 26916 22965 23013
Capital Lease Obligations 744 722 730 725 668
Deferred Income Tax 2752 2800 2795 2944 3479
Minority Interest 24 24 22 21 20
Other Liabilities, Total 4556 4901 5575 6498 7021
Total Equity 37197 37392 35789 37037 35134
Common Stock 387 387 387 387 387
Additional Paid-In Capital 35166 35163 35159 35155 35137
Retained Earnings (Accumulated Deficit) 1644 1842 243 1495 -390
Total Liabilities & Shareholders’ Equity 96086 96543 96687 96483 94185
Total Common Shares Outstanding 1549.91 1549.88 1549.85 1549.8 1549.51
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 2501 -265 3916 1548 1993
Cash From Operating Activities 9808 5963 4799 2969 2618
Cash From Operating Activities 5480 6530 3149 3762 3753
Non-Cash Items 542 141 -332 -103 -1276
Cash Taxes Paid 1623 1743 1562 1118 537
Cash Interest Paid 849 721 733 774 676
Changes in Working Capital 1285 -443 -1934 -2238 -1852
Cash From Investing Activities -2960 -11058 -285 -657 963
Capital Expenditures -2571 -2200 -2606 -2460 -1371
Other Investing Cash Flow Items, Total -389 -8858 2321 1803 2334
Cash From Financing Activities -6823 3649 -2203 -1765 -2044
Financing Cash Flow Items -1047 -178 -101 4 -67
Total Cash Dividends Paid -4364 -3856 -3572 -3592 -3484
Issuance (Retirement) of Stock, Net 29 29 30 3525 34
Issuance (Retirement) of Debt, Net -1441 7654 1440 -1702 1473
Foreign Exchange Effects -80 -62 12 5 -38
Net Change in Cash -55 -1508 2323 552 1499
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 2262 2501 1723 800 553
Cash From Operating Activities 3133 9808 7410 4480 3232
Cash From Operating Activities 1502 5480 4000 2666 1309
Non-Cash Items -391 542 172 15 -12
Cash Taxes Paid 225 1623 1335 1006 228
Cash Interest Paid 257 849 608 386 194
Changes in Working Capital -240 1285 1515 999 1382
Cash From Investing Activities -1246 -2960 -2711 -968 -168
Capital Expenditures -1470 -2571 -2017 -906 -363
Other Investing Cash Flow Items, Total 224 -389 -694 -62 195
Cash From Financing Activities -2031 -6823 -6465 -5035 -3740
Financing Cash Flow Items -840 -1047 -1047 -997 -997
Total Cash Dividends Paid -3047 -4364 -4364 -2971 -2971
Issuance (Retirement) of Stock, Net 4 29 11 8 5
Issuance (Retirement) of Debt, Net 1852 -1441 -1065 -1075 223
Foreign Exchange Effects -11 -80 -86 -35 -9
Net Change in Cash -155 -55 -1852 -1558 -685
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.5096 100893184 1200 2023-01-31 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.1998 65092368 768 2023-01-31 LOW
Investor AB Private Equity 3.3298 51608948 608 2023-01-31 LOW
Capital Research Global Investors Investment Advisor 3.1211 48374655 -165706 2023-06-15 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.8719 44511608 671315 2023-06-15 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.2154 34336042 875 2023-10-01 LOW
Capital World Investors Investment Advisor 1.8709 28997204 474010 2023-06-15 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 1.3307 20624979 125455 2023-10-01 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 1.1707 18144143 -35319 2023-10-01 LOW
GQG Partners, LLC Investment Advisor 1.0711 16600615 66511 2023-06-15 MED
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.9319 14443159 -63166 2023-10-01 LOW
State Street Global Advisors (UK) Ltd. Investment Advisor/Hedge Fund 0.7607 11789511 0 2023-10-01 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.6104 9460420 45825 2023-10-01 LOW
Nuveen LLC Pension Fund 0.5685 8811257 378713 2023-06-15 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5618 8707369 257289 2023-06-15 LOW
Aviva Investors Global Services Limited Investment Advisor/Hedge Fund 0.5266 8162319 -429899 2023-10-01 LOW
Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 0.5212 8078066 1670 2023-09-30 LOW
M&G Investment Management Ltd. Investment Advisor 0.4752 7364510 948 2023-10-01 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.4611 7146065 10590 2023-10-01 LOW
Union Investment Privatfonds GmbH Investment Advisor 0.4173 6467102 30000 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AstraZeneca - GBP Company profile

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.

Industry: Pharmaceuticals (NEC)

1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

Oil - Crude

78.23 Price
+0.180% 1D Chg, %
Long position overnight fee 0.0264%
Short position overnight fee -0.0483%
Overnight fee time 22:00 (UTC)
Spread 0.030

BTC/USD

61,228.05 Price
+1.050% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,089.50 Price
+1.540% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,046.33 Price
+0.590% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0112%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading